Bradlee Heckmann received his PhD from the Mayo Clinic College of Medicine and completed his post-doctoral fellowship at St. Jude Children’s Research Hospital under the mentorship of world-renowned immunologist Dr. Douglas Green. Together, Dr. Green and Dr. Heckmann identified a novel pathway of vesicle trafficking termed LC3-associated endocytosis and further found this pathway to be a critical regulator of innate immune activation and inflammation in macrophages and microglial cells. For his work, Dr. Heckmann has been nominated for and received multiple awards including a USERN Prize, AAAS Science Prize, and a Ruth Kirschstein National Research Service Award. In 2021 Dr. Heckmann was nominated as an international fellow of the Royal Society of Medicine. Dr. Heckmann’s ongoing work is directed at mapping neuroimmune architecture and regulatory pathways as well as developing novel cell-based therapeutics for diseases including Alzheimer’s Disease

Molecular and cellular mechanisms, neuroimmunity, neurodegenerative diseases, infections and cancer